Muñoz-Bellido F J, Moreno E, Dávila I
Allergy Service, Hospital Universitario de Salamanca, Spain.
Instituto Biosanitario de Salamanca, Salamanca, Spain.
J Investig Allergol Clin Immunol. 2022 Apr 19;32(2):97-115. doi: 10.18176/jiaci.0682. Epub 2021 Mar 3.
Recent advances in our understanding of T2 inflammation have revealed more diseases in which T2 inflammation is involved. Dupilumab is a recently developed monoclonal antibody that blocks signaling of IL-4 and IL-13, both of which are crucial cytokines in the T2 response. New possible indications are increasingly explored and include skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, as well as respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy, are also research fields of interest. Here, we review published data and clinical trials examining the use of dupilumab in these disorders.
我们对2型炎症认识的最新进展揭示了更多涉及2型炎症的疾病。度普利尤单抗是一种最近研发的单克隆抗体，可阻断IL-4和IL-13的信号传导，这两种细胞因子在2型反应中均至关重要。越来越多的新潜在适应症正在被探索，包括皮肤病，如结节性痒疹、钱币状湿疹、过敏性接触性皮炎、慢性手部湿疹、自发性慢性荨麻疹、大疱性类天疱疮、斑秃和 Netherton 综合征，以及呼吸道疾病，如变应性支气管肺曲霉病、慢性嗜酸性粒细胞性肺炎和变应性鼻炎。此外，嗜酸性粒细胞性胃肠道疾病，尤其是嗜酸性粒细胞性食管炎，以及食物过敏，也是备受关注的研究领域。在此，我们回顾已发表的数据以及关于度普利尤单抗在这些疾病中应用的临床试验。
